These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444 [TBL] [Abstract][Full Text] [Related]
25. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458 [TBL] [Abstract][Full Text] [Related]
27. Mifentidine: evaluation of antiandrogen effects and kidney function studies. Francalanza G; Franco C; Giachetti A Arzneimittelforschung; 1985; 35(1A):456-8. PubMed ID: 2859037 [TBL] [Abstract][Full Text] [Related]
28. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Sica DA Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888 [TBL] [Abstract][Full Text] [Related]
30. Antiandrogenic effect of spirolactones: mechanism of action. Corvol P; Michaud A; Menard J; Freifeld M; Mahoudeau J Endocrinology; 1975 Jul; 97(1):52-8. PubMed ID: 166833 [TBL] [Abstract][Full Text] [Related]
31. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297 [TBL] [Abstract][Full Text] [Related]
32. Anti-androgenic activity of spironolactone. Steelman SL; Brooks JR; Morgan ER; Patanelli DJ Steroids; 1969 Oct; 14(4):449-50. PubMed ID: 5344274 [No Abstract] [Full Text] [Related]
33. Comparative antiandrogenic potency of spironolactone and cimetidine: assessment by the chicken cockscomb topical bioassay. Hennessey JV; Glass AR; Barnes S; Vigersky RA Proc Soc Exp Biol Med; 1986 Sep; 182(4):443-7. PubMed ID: 3737611 [TBL] [Abstract][Full Text] [Related]
34. SC 23992: radioreceptor assays for therapeutic and side effects. Funder JW; Mercer J; Hood J Clin Sci Mol Med Suppl; 1976 Dec; 3():333s-334s. PubMed ID: 1071640 [TBL] [Abstract][Full Text] [Related]
35. Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro. Netchitailo P; Delarue C; Perroteau I; Leboulenger F; Capron MH; Vaudry H Biochem Pharmacol; 1985 Jan; 34(2):189-94. PubMed ID: 2981534 [TBL] [Abstract][Full Text] [Related]
37. Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men. Baba S; Murai M; Jitsukawa S; Hata M; Tazaki H J Urol; 1978 Mar; 119(3):375-80. PubMed ID: 642094 [TBL] [Abstract][Full Text] [Related]
38. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. McInnes GT; Shelton JR; Harrison IR Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797 [TBL] [Abstract][Full Text] [Related]